The aim of this study is to clarify the magnitude of the risk-to-benefit ratio with adjuvant therapy in high risk @entity5 . @entity1 AND METHODS: 162 @entity1 with pathologically documented @entity5 were randomly distributed into two groups. The first group (80 @entity1 ) received @entity416 for 6 cycles and the second group (82 @entity1 ) received FOLFOX4 for 6 cycles . All @entity1 in both groups were assessed for disease-free survival (DFS) and overall survival (OS) as regards to chemotherapy regimen and high risk factors. Tolerability and safety were assessed for all study population in both groups. RESULTS: Three-year DFS rates were 73% and 87% (Hazard ratio (HR)=2.051, 95%Cl(1.13-3.721) , P-value= 0.018), 3-year OS rates were 87% and 93% (P-value=0.26); corresponding 5-year OS rates for @entity1 with @entity34 were 34% and 93% (HR=2.555, 95%Cl(1.276-5.119), P-value=0.008) in the @entity416 and Folfox4 groups, respectively. Statistical significant differences in 5-year DFS and OS with lymph node sampling > 12 lymph nodes in favor Folfox4 group (HR=0.172, 95%Cl(0.0080- 0.370), P-value=<0.001) and (HR=0.087, 95%Cl(0.028-0.268), P-value=0.001) respectively. Multivariate analysis for all study population stated that the only significant risk factor was the inadequate lymph node sampling as regards to relapse (HR= 0.244, 95%CI (0.094-0.631), P-value=0.004) in @entity5 . @entity294 and @entity1897 ( @entity1897 ) were the most pronounced side effects in FOLFOX4 treatment arm. CONCLUSION: This study has demonstrated that @entity1 with @entity66 do behave more like stage III @entity694 @entity1 ; our data suggest that we must analyze @entity5 at this level if at all possible and those @entity1 with more than 12 lymph nodes resection should received adjuvant chemotherapy in favor of FOLFOX4 regimen with significant improvement in DFS which can be translated into an OS benefit.

Inadequate lymph node sampling as a risk factor in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['Capecitabine'] @entity66 :: ('MESH:D004194', 'Disease') :: ['microscopic disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage II colon cancer', 'tumors'] @entity294 :: ('MESH:D003967', 'Disease') :: ['Diarrhea'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral sensory neuropathy', 'PSN'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer'] @entity34 :: ('MESH:D016609', 'Disease') :: ['stage II disease']
@entity5 :: (MESH:D009369,Disease) :: ['stage II colon cancer']
